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Introduction 
Heart failure continues to be a serious health crisis with a current 
estimate of more than 37 million persons worldwide [1]. Of these, 
the prevalence of diabetes mellitus is 24% in patients with chronic 
heart failure and 40% in those hospitalized with debilitating heart 
failure. Chronic obesity and diabetes are potent mediators of diabetic 
cardiomyopathy [1,2]. A recently discovered adipokine, nephroblastoma 
overexpressed CCN3 (NOV/CCN3), is a multifunctional protein of the 
CCN family which is involved in many pathophysiological processes, 
including inflammation, interstitial fibrosis and renal tissue damage 
and repair [3]. NOV also modulates cell proliferation, cell adhesion 
activities and the subsequent induction of proinflammatory cytokines 
and chemokines in human cardio metabolic patients. Elevated NOV 
is attributed to increased obesity, plasma triglycerides and C-reactive 
protein [4]. Elevated NOV has also recently been associated with 
obstructive sleep apnea [5], a clinical syndrome that is strongly 
associated to obesity, insulin resistance and cardio-metabolic disease 
[5,6]. Abolition of NOV was found to decrease fat mass, improve 
glucose tolerance, insulin sensitivity, and to decrease proinflammatory 
cytokines and chemokines in adipose tissues of obese mice [7]. 
Impairment of mitochondrial energetics, increased reactive 
oxygen species (ROS) production and the resultant oxidative stress 
induces hypertension [8,9], and are considered primary risk factors 
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Abstract
We have previously shown that an Epoxyeicosatrienoic Acid (EET) -agonist has pleiotropic effects and reverses 
cardiomyopathy by decreasing inflammatory molecules and increasing antioxidant signaling. We hypothesized that 
administration of an EET agonist would increase Peroxisome proliferator-activated receptor-gamma coactivator 
(PGC-1α), which controls mitochondrial function and induction of HO-1 and negatively regulates the expression 
of the proinflammatory adipokines CCN3/NOV in cardiac and pericardial tissues. This pathway would be expected 
to further improve left ventricular (LV) systolic function as well as increase insulin receptor phosphorylation. 
Measurement of the effect of an EET agonist on oxygen consumption, fractional shortening, blood glucose levels, 
thermogenic and mitochondrial signaling proteins was performed. Control obese mice developed signs of metabolic 
syndrome including insulin resistance, hypertension, inflammation, LV dysfunction, and increased NOV expression 
in pericardial adipose tissue. EET agonist intervention decreased pericardial adipose tissue expression of NOV, 
while normalized FS, increased PGC-1α, HO-1 levels, insulin receptor phosphorylation and improved mitochondrial 
function, theses beneficial effect were reversed by deletion of PGC-1α. These studies demonstrate that an EET 
agonist increases insulin receptor phosphorylation, mitochondrial and thermogenic gene expression, decreased 
cardiac and pericardial tissue NOV levels, and ameliorates cardiomyopathy in an obese mouse model of the 
metabolic syndrome.
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in the development of diabetic cardiomyopathy [10]. Mitochondria 
play a major role in ROS generation and maintain an intricate balance 
between fusion and fission events [10]. The formation of interconnected 
mitochondrial networks via fusion allows for the replication and 
distribution of mtDNA across the reticulum, and is mediated by 
dynamin GTPases, mitofusin (Mfn1 and Mfn2 [10,11]. In contrast, the 
fission-induced dispersion of mitochondrial networks is governed by 
dynamin-related protein 1 (DRP1) and mitochondrial fission 1 (Fis1). 
Obesity and ROS induction contributes to a reduction in HO-1 
levels by either inherited or sedentary lifestyle-induced dyslipidemia, 
a decline in respiratory capacity, OXPHOS machinery, and ATP 
production [12-14], contributing to mitochondrial dysfunction and 
reduced energy expenditure [15-17]. Moreover, oxidative mutations 
of mitochondrial fusion and fission proteins disable the capability 
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of mitochondrial dynamics to maintain mtDNA integrity, further 
enhancing ROS-mediated oxidative stress [18,19]. 
A master regulator of mitochondrial biogenesis is peroxisome 
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), 
which regulates respiratory chain complexes and ATP synthases [20-
22]. PGC-1α levels in cardiomyocytes are critical to mitochondrial 
polarization, adequate output of ATP for cardiac energy supply, and 
increases in VO2 [22,23]. As excessive adipose tissue accumulation 
is a significant source of ROS and pro-inflammatory cytokines that 
may ultimately result in LV diastolic dysfunction, increased fibrosis 
and decreased contractility [14,24,25]. Ectopic fat accumulation 
and inflammation adjacent to the epicardium and pericardium has 
local deleterious effects on cardiac structure and function, further 
contributing to cardiomyopathy [24,26-28]. We previously showed 
that PGC-1α is regulated by EETs in adipocyte cells [29]. EETs are 
generated by a family of cytochrome P450 (CYP) monooxygenases and 
epoxygenases through their metabolism of arachidonic acid [30,31]. 
While ROS can rapidly hydrolyze EETs (reviewed in [14], EET agonists 
prevent both vascular complications and adiposity, while expansion of 
adipose tissue impairs the generation of EETs in vivo [32-35].
We hypothesize that the beneficial effect of EET-agonists on 
cardiac function is mediated by a reduction in the local secretion of 
inflammatory molecules such as NOV by pericardial fat, accompanied 
by upregulation of PGC-1α and HO-1 and amelioration of obesity-
mediated cardiomyopathy. We further hypothesize that EET 
upregulation may change the pericardial adipocyte phenotype from 
white to beige-like adipocytes resulting in increased expression of 




Generation of PGC-1α-deficient cells using lentivirus: 3T3-L1 
murine pre-adipocytes were purchased from ATCC (ATCC, Manassas, 
VA). Cells were cultured in α-minimal essential medium (α-MEM, 
Invitrogen, Carlsbad CA) supplemented with 10% fetal bovine serum 
(FBS, Invitrogen, Carlsbad, CA) and 1% antibiotic/antimycotic 
solution (Invitrogen, Carlsbad, CA). The cultures were maintained at 
37°C in a 5% CO2 incubator and the medium was changed after 48 h 
and every 3~4 days thereafter, as described previously [29]. SMART 
vector lentiviral shRNA-PPARGC1A or scrambled RNA (Dharmacon, 
Lafayette, CO) was applied to 3T3-L1 cells to establish a stably 
transduced cell line, as described [29].
Animal protocols
We used db/db mice as a model of obesity induced diabetic 
cardiomyopathy as these mice develop insulin resistance, hyperglycemia 
and fail to control gluconeogenesis, leading to peripheral neuropathy 
and myocardial disease. Sixteen week old male db/db mice, on 
C57BL/6J background (Jackson Labs, Bar Harbor, ME), were divided 
into four treatment groups, 6 mice per group, following a 16-week 
acclimatization period weighing approximately 54 g at the start of the 




• EET-agonist plus Ln-PGC-1α-shRNA
Age-matched C57BL/6J mice (C57) (Jackson Labs) were used as 
WT (lean, C57) controls. All mice were fed regular (Harlan, Teklad Lab 
Animal Diets, US). Mice (db/db) were treated as follows:
• Control
• Administered 2 bolus injections of 40-70 x 106 TU/mouse in 
80-100 μl of Ln-non-target-shRNA (Dharmacon, Lafayette, 
CO, US) into the retro orbital vein, 
• Injected intraperitoneally with the EET-agonist twice/week for 
eight weeks at a dose of 15 mg/kg body weight, 
• EET-agonist and administered 2 bolus injections 40-70 x 106 
TU/mouse in 80-100 μl PGC-1α (sh) lentivirus (Dharmacon) 
into the retro orbital vein at 3 and 5 weeks after the start of 
EET-agonist injections.
At the end of the study, mice were euthanized with ketamine 
(100 mg/kg)/xylazine (10 mg/kg) administration followed by cervical 
dislocation. Body weight and fat content were measured at sacrifice. 
All animal studies have been approved by the appropriate ethics 
committees of the NYMC, IACUC institutionally approved protocol in 
accordance with the NIH guidelines.
Fasting blood glucose, glucose tolerance test and blood pressure 
measurement
Fasting blood glucose measured following a 6 h fast. For the glucose 
tolerance test, mice were injected intraperitoneally with glucose (2.0 
g/kg body weight) after which blood glucose was measured every 30 
minutes up to 120 min. Blood pressure measured using standard tail-
cuff method [36]. 
Echocardiogram measurement of fractional shortening 
Echocardiography was performed using a 12-MHz probe on 
isoflurane anesthetized mice. Images of the left ventricular (LV) 
diameter was obtained in M-mode and used to measure the end-
diastolic and end-systolic diameters from which the LV fractional 
shortening was calculated [36]. 
Determination of oxygen consumption and respiratory 
quotient
The Oxylet gas analyzer and air flow unit (Oxylet; Panlab-Bioseb, 
Vitrolles, France) was used to determine individual mouse VO2 and 
RQ as previously described [36].
ATP and mitochondrial copy number measurement 
ATP content was quantified in heart tissue (10 mg/mouse) using 
an ATP Colorimetric Assay Kit (ABCAM, Cambridge, MA) as per 
the instructions provided by the manufacturer. Mouse Mitochondrial 
DNA Copy Number Kit (Detroit R&D, Inc., Detroit, MI) was used to 
measure mtDNA Copy Number.
Real-time qPCR and western blot analysis 
For real-time PCR analysis total RNA was extracted from heart 
and pericardial fat tissues with TRIzol® (Ambion, Austin, TX). A High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was 
used to synthesize cDNA from total RNA. Specific TaqMan® Gene 
Expression Assay probes (Fisher Scientific, Waltham, MA) for mouse 
PGC-1α, HO-1, NOV/CCN3, COX-1, PRDM16, CCL2, Adiponectin, 
TNFα, IL-6 and GAPDH were used as previously described. For 
Western blot, tissues were first lysed in RIPA buffer supplemented 
with protease and phosphatase inhibitors (Complete™ Mini and 
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PhosSTOP™, Roche Diagnostics, Indianapolis, IA) and total protein 
content was analyzed by the Bradford method (BIO-RAD, Hercules, 
CA). Immunoblotting was performed for select proteins [18,36].
Measurement of HO and EET levels
Heart tissue was lysed in RIPA lysis buffer, CO released and EET 
levels were analyzed as previously described [18,36,37].
Statistical analysis
Data values are expressed as means ± S.E.M. Student’s t-test was 
used for pairwise comparison and one-way ANOVA with Bonferroni’s 
post-test for comparison was used to calculate the significance of 
mean value differences using one-way analysis of variance. The null 
hypothesis was rejected at p<0.05.
Results
EET-agonist administration increases endogenous EET levels 
and improves metabolic function
Although the db/db mice treated with the EET agonist ate the 
same amount of food as the other groups during treatment, they 
weighed significantly less at the experimental endpoint 45.2 ± 1.33 
g, than control mice (p<0.05) (63.9 ± 1.58 g). Knockdown of PGC-
1α reversed the beneficial effect of EET-agonist with mice weighing 
54.9 ± 3.65 g at the experimental endpoint (Table 1). Fasting blood 
glucose in the db/db control, and EET-agonist and EET-agonist 
with PGC-1α (sh) treated mice was 355 ± 22.2 mg/dL, 134 ± 6.5 
mg/dL, and 205 ± 5.5 mg/dL, respectively (Table 1). Knockdown of 
PGC-1α reversed the effects of EET-agonist treatment. As seen in 
Table 1, EET-A treatment of db/db mice improved (p<0.05) glucose 
tolerance as compared to db/db control, an effect that was inhibited 
in ln-PGC-1α (sh) db/db mice.
Blood pressure was reduced (p<0.05), oxygen consumption 
increased (p<0.05), and the CO2/O2 ratio was decreased with EET-
agonist treatment (p<0.05) (Table 1). These EET-agonist-mediated 
effects were significantly reduced in EET-agonist-treated mice 
administered Ln-PGC-1α (sh). Obesity was associated with an increase 
in heart weight as compared to mice treated with the EET-agonist alone 
(0.16 ± 0.004 vs. 0.13 ± 0.001, respectively), while the EET-agonist in 
combination with decreased levels of PGC-1α prevented the beneficial 
effect of EET-agonist on heart weight (0.14 ± 0.006) (Table 1).
Importantly, EET-agonist is known to inhibit sEH, and therefore 
may directly result in the observed elevation of endogenous cellular 
levels of EET in cardiac tissues, an effect that was prevented in PGC-
1α-deficient mice treated with EET-agonist (Table 1).
Glucose tolerance was improved (p<0.05) in db/db mice treated 
with EET-agonist with a decrease in fasting glucose, suggesting 
increased insulin sensitivity (p<0.05) (Table 1). This was partially 
prevented (p<0.05) in PGC-1α-deficient db/db mice (Table 1).
EET-agonist treatment restores cardiac function and associated 
signaling pathways
Cardiac function, as measured by echocardiography and 
calculation of fractional shortening (FS), was significantly impaired 
(p<0.05) in control db/db mice as compared to lean WT (C57) (Figure 
1A and B). Fractional shortening was improved (p<0.05) in db/db mice 
treated with EET-agonist (p<0.05) (Figure 1A and B), an effect that was 
partially prevented (p<0.05) in PGC-1α-deficient db/db mice (Figure 
1A and B). Injection of db/db mice with saline and non-target lentiviral 
vector (vehicle and vector controls) had no effect on FS as compared to 
control db/db mice (Figure 1A and B).
Cardiac tissues from control db/db mice expressed lower levels 
(p<0.05) of pAMPKα and pIR972 as compared to C57 (WT C57Bl6) 
mice (Figure 1C-E). Decreased phosphorylation of AMPKα in db/db 
mice was associated with a reduction in phosphorylation of the insulin 
receptor (Figure 1E). HO-1 and PGC-1α protein levels in db/db mice 
were lower (p<0.05) compared to C57 mice (Figure 1F-H). Decreased 
levels of HO-1 and PGC-1α in db/db mice were associated with an 
increase in Fis, indicative of increased mitochondrial fission (Figure 
1I). As seen in Figure 1 treatment of db/db with saline and non-target 
lentiviral vector (vehicle and vector controls) had no effect on any of 
the protein levels as compared to control db/db mice.
EET-agonist administration causes reduction of NOV 
expression
Basal levels of pericardial adipose tissue expression of NOV were 
significantly higher than in visceral fat (p<0.05) (Figure 2A). Cardiac 
tissues expressed the highest levels of NOV compared to kidney and 
liver (p<0.05) (Figure 2B). EET-agonist administration decreased 
NOV in cardiac and pericardial adipose tissues (Figure 2C and D). 
Importantly, a reduction in PGC-1α reversed the ability of EET-agonist 
Control EET-A EET-A+Ln-PGC1α(sh)
Body Weight (g) 63.9 ± 1.58 45.2 ± 1.33* 54.9 ± 3.65#
Food Intake (g) 15.2 ± 0.30 14.9 ± 0.59 15.4 ± 0.91
Fasting Blood Glucose (mg/dL) 355 ± 22.2 134 ± 6.5* 205 ± 5.5#
Heart Weight (g) 0.16 ± 0.004 0.13 ± 0.001* 0.14 ± 0.006
Blood Pressure (mmHg) 161.9 ± 4.19 110.3 ± 3.58* 137.9 ± 2.59#
VO2 (mL/Min) 25.31 ± 0.501 34.70 ± 7.35* 26.01 ± 13.01#
RQ (CO2 Eliminated/O2 Consumed) 0.81 ± 0.005 0.75 ± 0.007* 0.82 ± 0.017#
EET levels in Cardiac tissue (pg/μg of protein) 50.93 ± 9.58 83.33 ± 5.10* 55.36 ± 2.15#
Glucose Tolerance Test: Mean ± SEM Blood Glucose levels (mg/dl)
Group 0 30 60 90 120
Control 355.5 ± 19.3 550.0 ± 8.8 600.0 ± 0.0 557.3 ± 13.2 541.8 ± 7.0
EET-A 134.0 ± 6.1 316.0 ± 5.7 339.3 ± 10.6 276.0 ± 23.0 237.7 ± 27.6
EET-A+Ln-PGC-1α (sh) 205.3 ± 5.2 388.3 ± 40.7 388.0 ± 5.7 372.3 ± 18.7 305.0 ± 4.0
Lean 115.0 ± 4.5 318.8 ± 34.6 247.8 ± 16.1 169.3 ± 14.7 135.3 ± 10.7
Table 1: Metabolic parameters in db/db mice (Table showing food intake, final body weight, fasting blood glucose as well as glucose tolerance test, heart weight, blood 
pressure, and oxygen consumption as well as respiratory quotient, and endogenous EET levels in cardiac tissues of control, EET-agonist treated, and EET-agonist treated 
PGC-1α-deficient db/db mice. Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist alone).
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Figure 1: EET-agonist treatment improves left ventricular dilation, fractional shortening, and glucose tolerance. (A) Sample M-mode short axis echocardiographic 
images showing LV dilation and FS in wild-type (C57) and db/db control, db/db non-target and vehicle (saline) injected, db/db treated with EET-agonist, and PGC-
1α-deficient db/db mice treated with EET-agonist; (B) Graph depicting left ventricular fractional shortening in each cohort (n=6, **p<0.05 vs. C57, *p<0.05 vs. control 
and #p<0.05 vs. EET-agonist). Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist. Representative blots; (C) 
and densitometric analysis of (D) pAMPKα/AMPKα, and (E) pIR972, representative blots (F) and densitometric analysis of (G) HO-1, (H) PGC-1α, and (I) Fis1 in 
WT (C57), db/db control and db/db non-target and vehicle (saline) injected mice. Results are mean ± SE, n=6, *p<0.05 vs. C57 mice.
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to reduce NOV in both cardiac and pericardial adipose tissues (Figure 
2C and D). A similar trend was observed in visceral adipose tissue 
(Figure 2E).
PGC-1α knockdown prevented EET-agonist-mediated 
increase in Sirt1, phosphorylation of AMPKα, and IR972 in 
cardiac tissue
Figure 3A shows efficient lentivirus-mediated knockdown 
of PGC-1α in 3T3-L1 derived adipocytes in vitro. EET-agonist-
mediated induction of PGC-1α, HO-1 expression and HO-activity, 
was associated with a decrease in NOV expression (Figure 3B-F). 
EET-agonist led to a 2-fold upregulation of PGC-1α in cardiac tissues 
compared to control mice (Figure 3B and C). The EET- agonist-
mediated increase in PGC-1α levels was prevented in Ln-PGC-1α (sh) 
mice (Figure 3B and C). HO-1 levels were increased in EET-agonist 
treated mice compared to control mice (p<0.05) (Figure 3B and D). 
Ln-PGC-1α (sh) in EET-treated mice prevented the EET-agonist-
mediated induction of HO-1 expression and reduced it to the level 
of db/db control mice (Figure 3B and D). The effect of EET-agonist 
and PGC-1α knockdown on HO-1 protein levels was paralleled by 
measurement of HO-activity (Figure 3E). Importantly, NOV protein 
levels were reduced (p<0.05) (Figure 3F) in cardiac tissue of EET-
agonist treated mice, an effect reversed in PGC-1α-deficient mice, 
confirming the changes observed in mRNA levels (Figure 2). EET-
agonist treatment increased Sirt1 and phosphorylation of both 
AMPKα (Thr172) and AKT (Ser473) levels (p<0.05) mediating 
an increase in insulin receptor phosphorylation and prevented by 
lentivirus-mediated silencing of PGC-1α (Figure 3G-K).
Increased EET-levels in cardiac tissues improves mitochondrial 
function and biogenesis
EET-agonist increased Mfn2 expression and decreased Fis1 
(Figure 4A-C). The EET-agonist-mediated effect on Mfn2 and Fis1 
was reversed in PGC-1α-deficient mice (Figure 4A-C). The levels of 
DRP1 were not impacted by either EET-agonist or lentivirus-mediated 
suppression of PGC-1α (Figure 4A and D). EET-agonist improved 
both mitochondrial function and biogenesis in cardiac tissues of EET-
agonist treated mice as assessed by the increase in ATP generation and 
mitochondrial copy number. In contrast, in cardiac tissues of PGC-
1α-deficient mice treated with EET-agonist both ATP generation and 
mitochondria copy number were significantly (p<0.05) decreased 
(Figure 4E and F). Furthermore, EET-agonist increased mRNA 
expression levels of an antioxidant gene MnSOD2 in cardiac tissue of 
mice, the beneficial effects of EET was abolished by lentivirus-mediated 
suppression of PGC-1α (Figure 4G).
EET-agonist treatment reduces inflammatory cytokines levels 
and cardiac remodeling (MMP2)
The cardiac expression of MMP-2 protein was reduced in EET-
agonist treated db/db mice compared to control db/db mice (p<0.05), 
which was prevented by Ln-PGC-1α (sh) (Figure 5A and B). EET-
agonist-mediated decrease of MMP-2 may explain the prevention of 
cardiac remodeling, an effect reversed by silencing of PGC-1α (Figure 
5A-D). TNFα and IL-6 in cardiac tissues of EET-agonist treated db/db 
mice were reduced compared to cardiac tissues of control db/db mice 
(Figure 5A-D), a result similar to pericardial fat tissue.
 





































































































































Figure 2: Expression of NOV in different tissues of control db/db mice. (A) NOV mRNA expression in pericardial fat and visceral fat; (B) NOV mRNA expression 
in heart, kidney and liver; (C) Effect of EET-agonist treatment on NOV mRNA expression levels in heart of individual mouse, Effect of EET-agonist treatment on 
NOV mRNA expression in (D) Pericardial fat and (E) Visceral fat of db/db control mice, db/db treated with EET-agonist mice, and PGC-1α-deficient db/db mice 
treated with EET-agonist. Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.
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EET-agonist administration increases thermogenic and 
mitochondrial genes in pericardial adipose tissues
The effect of EET-agonist on cardiac tissue extended to 
pericardial adipose tissue. This is evidenced by increased levels of 
HO-1, PGC-1α, and PRDM16 (thermogenic genes), and increased 
mitochondrial function (COX-I) in pericardial adipose tissue 
(Figure 6A-D). EET-agonist treated db/db mice exhibited increased 
PGC-1α mRNA levels compared to db/db control mice (p<0.05), 
whereas PGC-1α mRNA expression in pericardial adipose tissue of 
EET-agonist-PGC-1α (sh) db/db mice was, as expected, lower than 
control db/db mice (p<0.05; Figure 6A). EET-agonist increased 
HO-1 mRNA levels compared to control mice (p<0.05), that was 
prevented in Ln-PGC-1α (sh) mice (Figure 6B). COX-I mRNA 
levels increased in EET-agonist treated mice (p<0.05) compared to 
control mice, that was prevented in Ln-PGC-1α (sh) mice (Figure 
6C). PRDM16 is a thermogenic gene responsible for the conversion 
of white fat to brown fat. EET-agonist treated mice expressed higher 
PRDM16 mRNA levels as compared to control mice (p<0.05), while 
lentiviral-mediated suppression of PGC-1α reversed the effect of 
EET-agonist treatment (Figure 6D). Similarly, there was an increase 
in adiponectin levels and decrease in TNF-α, IL-6 and the monocyte 
chemoattractant CCL2 (Figure 6E-H). Adiponectin mRNA levels 
were upregulated in mice administered EET-agonist as compared 
to control mice (p<0.05), an effect that was blocked in PGC-
1α-deficient mice (Figure 6E). EET-agonist treated db/db mice 
exhibited a decrease in TNF-α, IL-6 and CCL2 mRNA expression 
levels in pericardial adipose tissue as compared to control mice 
(p<0.05), while lentivirus-mediated silencing of PGC-1α prevented 









































































































































































































Figure 3: Effect of EET-agonist treatment on levels of PGC-1α, HO-1, NOV Sirt1, pAMPKα, total AMPKα, pAKT, total AKT and pIR972 in cardiac tissue of db/db 
mice. (A) PGC-1α mRNA levels in control (WT) and lentivirus-mediated knockdown of PGC-1α in 3T3-L1-derived adipocytes. Representative western blots; (B) 
and G) and densitometric analysis of (C) PGC-1α, (D) HO-1, (E) HO-activity as measured by CO generation, (F) NOV, (H) Sirt1, (I) pAMPKα/AMPKα, (J) pAKT/
AKT, and (K) pIR972 in cardiac tissues of db/db control mice, db/db mice treated with EET-agonist, and PGC-1α-deficient db/db mice treated with EET-agonist. 
Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.
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Figure 4: Effect of EET-agonist treatment on mitochondrial function and biogenesis in cardiac tissue of db/db mice. (A) Representative western blots, densitometric 
analysis of (B) Mfn2; (C) Fis1, and (D) DRP1, (E) ATP levels, (F) mitochondrial copy number; (G) mRNA expression of an antioxidant gene MnSOD2 in cardiac 
tissues of db/db control mice, db/db mice treated with EET-agonist, and PGC-1α-deficient db/db mice treated with EET-agonist. Results are mean ± SE, n=6, 
*p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.
Discussion
This report demonstrates that an EET agonist increases PGC-1α-
HO-1, associated with increased insulin receptor phosphorylation, 
a decrease in fasting blood glucose and a reduction in pericardial 
fat deposition while decreases cardiac and pericardial fat NOV 
expression. Pericardial adipose tissue is a metabolically active organ 
that secretes several adipokines including NOV that may be linked to 
LV dysfunction. EET mediated decrease in NOV and the concurrent 
increase in PGC1a-HO-1 results in an increase in thermogenic genes 
and improved mitochondrial biogenesis and function. Importantly, 
this suggests that EET-mediated decreases in local expression of NOV 
in pericardial fat may have a direct effect on LV fractional shortening.
EET-agonist treatment produced an improvement in left 
ventricular FS, an effect that was reversed in mice with reduced levels of 
PGC-1α and increased levels of NOV. These results are in accordance 
with previous observations that PGC-1α deficiency caused LV dilation 
and poor cardiac contractility [38], insulin resistance and increased 
circulating lipid levels [39]. Our results suggest a new function for 
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Figure 5: Effect of EET-agonist treatment on inflammatory cytokine and MMP2 levels in cardiac tissue of db/db mice. Representative blots (A) and densitometric 
analysis of (B) MMP2, (C) IL-6, and (D) mRNA expression of TNF-α in cardiac tissue of db/db control mice, db/db mice treated with EET-agonist, and PGC-1α-
deficient db/db mice treated with EET-agonist. Results are mean ± SE, n=6, *p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.
EET that is associated with a decrease in NOV levels. Additionally, we 
demonstrate that EET-mediated suppression of pericardial fat secretion 
of NOV accompanied by increased expression of PGC-1α –HO-1 
and adiponectin. Thus, there seems to be an opposing relationship 
between NOV and adiponectin, both in terms of expression and effect 
on adipocyte maturation and function. Increased NOV in obesity 
may potentiate adipocyte inflammation and hyperplasia that in turn 
further increases inflammatory adipokines. EET-mediated decrease of 
NOV and increase in PGC-1α-HO-1 expression results in improved 
metabolic parameters in db/db mice highlighting that NOV, PGC-
1α and HO-1 are inter-related and have a major relationship in the 
development of cardiomyopathy. NOV regulates various inflammatory 
molecules, which impair insulin signaling and promote insulin 
resistance. Increased NOV levels are associated with obesity, fat 
deposition and insulin resistance in human cardio metabolic patients 
[4]. Our results are supported by the observation that low levels of NOV 
are associated with increased PGC-1α expression, decreased fat mass, 
increased insulin sensitivity and decreased inflammation in adipose 
tissue of mice fed a HFD [7]. However, the reciprocal relationship 
between PGC-1α and NOV in pericardial fat and the high levels of 
NOV in pericardial adipose tissue compared to the heart, suggest that 
the regulation of NOV in pericardial adipose tissue is different from 
that in cardiac tissue.
We demonstrate that EET mediated increases in PGC-1α results 
in an increase in Mfn2, cytochrome C oxidase and ATP levels, which 
identify PGC-1α as a major regulator of mitochondrial function 
[18,36]. Since HO-1 enhances mitochondrial integrity and function 
and EET-agonist treated mice deficient in PGC-1α display diminished 
levels of HO-1, reduced levels of Mfn2, ATP, COX-I, and increased 
levels of Fis1 make it is likely that EET mediates signaling through 
the PGC-1α and HO-1 pathway. This also confirms that PGC-1α is 
upstream of HO-1, and is therefore primarily responsible for the HO-1 
mediated decrease of pro-oxidants including excess heme seen in vitro 
and in animal models of obesity [34,35]. Heme abatement results in 
decreased levels of ROS and oxidative stress, both known causes of 
mitochondrial fragmentation and cardiomyopathy [12,40]. Reduction 
of HO-1 expression increases heme-mediated ROS levels, resulting in 
an increase in inflammation [40,41]. HO-1 deficiency causes organ 
damage in humans and mice [42]. Importantly, gene polymorphisms 
that negatively regulate the global as well as monocyte-specific HO-1 
expression has been shown to be associated with the risk of CVD and 
atherosclerosis [43,44]. Further, ablation of HO-1 in adipose-specific 
HO-1 knockout increases ROS through inhibition of mitochondrial 
fusion and PGC-1α [18]. HO-1 degrades heme to ferrous iron, 
biliverdin and CO and recent studies indicate that increased HO 
activity, bilirubin and CO production reduces oxidative stress, and 
pathological remodeling of the heart [25,45]. HO-1 and CO provides 
cardioprotection [46], reduces infarct size [47], and protects human 
stem cells against cell death [48]. The protective effects of increased 
HO activity also prevent mitochondrial DNA depletion and improved 
mitochondrial quality control [34,40]. HO-activity plays an important 
role in mitochondrial electron transport, biogenesis and viability 
[12,49]. The observation that EET-agonist increases mitochondrial 
fusion and decreases mitochondrial fission supports the contention 
that HO activity is mediated by PGC-1α, and is consistent with prior 
observations that increased HO-1 levels, as well as CO-releasing 
molecules, exert cardio-protective, anti-fibrotic, and anti-apoptotic 
effects in both ischemic and non-ischemic cardiomyopathy [46,50]. 
A relationship between pericardial fat and cardiac contractility is 
supported by the observation that EET-agonist reduced pericardial 
adipose tissue deposition, NOV, and TNF-α, IL-6 and CCL2 levels. 
EETs possess the ability to reprogram pericardial fat, altering phenotype 
from inflammatory white to healthy functional beige adipocytes with 
increased adiponectin levels and normal mitochondrial function 
that express thermogenic genes. These include PRDM16, responsible 
for the attenuation of cardiac remodeling and cardiomyopathy and 
associated with increased energy expenditure in, and browning of, 
adipose tissue, leading to synthesis of adipokines and obesity [51]. 
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Figure 6: Effect of EET-agonist treatment on levels of PGC-1α, HO-1, COX-I and PRDM16, adiponectin, TNF-α, IL-6, and CCL2 in pericardial adipose tissues of 
db/db mice. mRNA levels of (A) PGC-1α, (B) HO-1, (C) COX-I, (D) PRDM16, (E) Adiponectin, (F) TNF-α, (G) IL-6, and (H) CCL2. Results are mean ± SE, n=6, 
*p<0.05 vs. db/db control, #p<0.05 vs. db/db mice treated with EET-agonist.
Ectopic fat accumulation within and around the heart increases 
risk of cardiomyopathy associated with mitochondrial dysfunction, 
highlighting the complex relationship between obesity, insulin 
resistance and cardiac LV abnormalities [24,26-28,52]. Pericardial 
and epicardial adipose tissues are a major source of adipokines, 
inflammatory cytokines and ROS, which can contribute to cardiac 
remodeling [53]. 
EET-induced PGC-1α activation reduced the levels of MMP-2 in 
cardiac tissue, providing mechanistic support for prior observations 
that EET decreases cardiac fibrosis [25]. EET-related decrease in MMP-
2 and improvement in FS is accompanied by activation of AKT and 
AMPK in cardiac tissue. Likewise, in metabolic organs such as the liver, 
adipose tissue, and skeletal muscle, activation of AMPK stimulates 
catabolic and inhibit anabolic processes [54]. EET-agonists offer a 
unique multifactorial clinical approach to prevention and treatment 
of diabetic cardiomyopathy and concomitant metabolic derangements 
(Figure 7).
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Figure 7: Schematic description of the EET mediated NOV-PGC-1α-HO-1 in 
mitochondrial biogenesis and function, and thermogenic genes PRDM16. EET-
mediated change of pericardial fat phenotype and increase in to expression of 
mitochondrial signaling protein, thermogenic genes similar to that described to 
beige type like adipose tissue. The EET-agonist-mediated reduction in NOV 
subsequently increases PGC-1α and HO-1 leads to increased ATP production, 
oxygen consumption, increased mitochondrial fusion, DNA copy number, 
insulin sensitivity that all in concert leads to an improvement in cardiac function.
The clinical ramifications of this pathway are substantial, given 
its ability to reduce body fat mass, restore glucose homeostasis, 
inhibit the generation of ROS, reduce adipose tissue inflammation, 
enhance mitochondrial function and most importantly, restore 
myocardial function. This study demonstrates for the first time that 
EET upregulation of PGC-1α inhibits NOV, and prevents increased 
expression of inflammatory markers through upregulation HO-1 
in both the heart and pericardial adipose tissue, thwarting the 
development of cardiomyopathy. Hence, the EET-agonist-mediated 
reduction of NOV identifies it as a novel pharmacologic target to treat 
myocardial dysfunction caused by obesity and diabetes mellitus.
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